Cho Sehyung, Kagan Benjamin L, Blackford John A, Szapary Daniele, Simons S Stoney
Steriod Hormones Section, National Institute of Diabetes and Digestive and Kidney Diseases/LMCB, National Institutes of Health, Bethesda, Maryland 20892, USA.
Mol Endocrinol. 2005 Feb;19(2):290-311. doi: 10.1210/me.2004-0134. Epub 2004 Nov 11.
Several factors modulate the position of the dose-response curve of steroid receptor-agonist complexes and the partial agonist activity of antagonist complexes, thereby causing differential gene activation by circulating hormones and unequal gene repression during endocrine therapies with antisteroids. We now ask whether the modulatory activity of three factors (homologous receptor, coactivator transcription intermediary factor 2, and Ubc9) requires the same or different domains of glucocorticoid receptors (GRs). In all cases, we find that neither the amino terminal half of the receptor, which contains the activation function-1 activation domain, nor the DNA binding domain is required. This contrasts with the major role of activation function-1 in determining the amount of gene expression and partial agonist activity of antisteroids with most steroid receptors. However, the situation is more complicated with Ubc9, where GR N-terminal sequences prevent the actions of Ubc9, but not added GR or transcription intermediary factor 2, at low GR concentrations. Inhibition is relieved by deletion of these sequences or by replacement with the comparable region of progesterone receptors but not by overexpression of the repressive sequences. These results plus the binding of C-terminal GR sequences to the suppressive N-terminal domain implicate an intramolecular mechanism for the inhibition of Ubc9 actions at low GR concentrations. A shift from noncooperative to cooperative steroid binding at high GR concentrations suggests that conformational changes reposition the inhibitory N-terminal sequence to allow Ubc9 interaction with elements of the ligand binding domain. Collectively, these results indicate a dominant role of GR C-terminal sequences in the modulation of the dose-response curve and partial agonist activity of GR complexes. They also reveal mechanistic differences both among individual modulators and between the ability of the same factors to regulate the total amount of gene expression.
多种因素可调节类固醇受体 - 激动剂复合物剂量 - 反应曲线的位置以及拮抗剂复合物的部分激动剂活性,从而导致循环激素引起不同的基因激活,以及在使用抗类固醇进行内分泌治疗期间基因抑制程度不均。我们现在要问,三种因素(同源受体、共激活因子转录中介因子2和Ubc9)的调节活性是否需要糖皮质激素受体(GRs)的相同或不同结构域。在所有情况下,我们发现受体的氨基末端一半(包含激活功能-1激活结构域)和DNA结合结构域均不需要。这与激活功能-1在确定大多数类固醇受体的抗类固醇基因表达量和部分激动剂活性方面的主要作用形成对比。然而,Ubc9的情况更为复杂,在低GR浓度下,GR的N端序列会阻止Ubc9的作用,但不会阻止添加的GR或转录中介因子2的作用。通过删除这些序列或用孕酮受体的可比区域替换可解除抑制,但通过抑制序列的过表达则不能。这些结果加上GR的C端序列与抑制性N端结构域的结合,暗示了一种在低GR浓度下抑制Ubc9作用的分子内机制。在高GR浓度下从非协同类固醇结合转变为协同结合表明,构象变化会重新定位抑制性N端序列,以允许Ubc9与配体结合结构域的元件相互作用。总体而言,这些结果表明GR的C端序列在调节GR复合物的剂量 - 反应曲线和部分激动剂活性方面起主导作用。它们还揭示了各个调节剂之间以及相同因素调节基因表达总量能力之间的机制差异。